Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Urogenital aging: solutions in clinical practice

M Notelovitz1

  • 1Women's Medical and Diagnostic Center, Gainesville, Florida, USA.

International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics
|January 10, 1998
PubMed
Summary

Urogenital aging affects many postmenopausal women, causing discomfort and reduced quality of life. Vagifem, a new 17beta-estradiol vaginal tablet, offers a convenient and localized treatment option for vaginal symptoms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estradiol absorption from vaginal tablets in postmenopausal women.

Obstetrics and gynecology·2002
Same author

Effects of estrogen/androgen therapy on bone mineral density parameters.

The Journal of reproductive medicine·2001
Same author

Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17beta-estradiol.

Menopause (New York, N.Y.)·2000
Same author

The effect of site of application on the transcutaneous absorption of 17-beta estradiol from a transdermal delivery system (Climara).

Menopause (New York, N.Y.)·2000
Same author

Urogenital atrophy and low-dose vaginal estrogen therapy.

Menopause (New York, N.Y.)·2000
Same author

Initial 17beta-estradiol dose for treating vasomotor symptoms.

Obstetrics and gynecology·2000

Area of Science:

  • Gynecology
  • Menopause research
  • Vaginal health

Background:

  • Urogenital aging is a common menopause consequence impacting over 50% of postmenopausal women.
  • Symptoms include reduced quality of life, sexual dysfunction, pain, and incontinence.
  • This condition remains significantly undertreated.

Purpose of the Study:

  • To evaluate Vagifem, a novel vaginal tablet containing 25 mcg of 17beta-estradiol.
  • To assess its potential as an ideal treatment for urogenital atrophy symptoms.
  • To determine if it meets criteria for localized, convenient, and safe endometrial treatment.

Main Methods:

  • Administration of Vagifem, a vaginal tablet.
  • Dosage: 25 mcg 17beta-estradiol.
  • Focus on localized vaginal application.

Related Experiment Videos

Main Results:

  • Vagifem provides localized relief of vaginal estrogen deficiency symptoms.
  • The tablet form offers convenience and ease of application.
  • Potential for endometrial safety and reduced discharge compared to other methods.

Conclusions:

  • Vagifem may fulfill criteria for effective urogenital atrophy management.
  • It presents a promising option for postmenopausal women experiencing vaginal symptoms.
  • Further research may confirm its benefits in improving quality of life.